Mount Sinai’s Woojin Han, PhD, Receives NIH Stephen I. Katz Early Stage Investigator R01 Award
$2 million grant will fund efforts to engineer an asymmetric hydrogel for muscle stem cell polarity and fate specification
A Mount Sinai researcher has been awarded a five-year, $2.2 million grant from the National Institutes of Health (NIH) to expand skeletal muscle stem cells in culture, work that could someday be used to treat skeletal muscle injuries, sarcopenia, muscular dystrophy, and other muscle injuries and disorders.
The researcher, Woojin Han, PhD, is an Assistant Professor in the Leni and Peter W. May Department of Orthopedics at the Icahn School of Medicine at Mount Sinai. He plans to engineer an asymmetric designer hydrogel for expanding self-renewing muscle stem cells ex vivo by directing cellular polarity, which regulates how stem cells divide to make more stem cells or differentiate to give rise to new muscle fibers, a turning point known as stem cell fate specification.
The NIH’s Stephen I. Katz Early Stage Investigator Research Project Grant supports an innovative project in an area of science that represents a change in research direction for an early-stage investigator and for which no preliminary data exist.
“We are very honored and excited to receive this award,” said Dr. Han. “Muscle stem cell transplantation has potential to treat muscle trauma and diseases, including Duchenne muscular dystrophy and cancer cachexia. But limited cell source remains a tremendous challenge for its translation into practice. This five-year grant will allow us to better understand how muscle stem cells interact with their asymmetric microenvironment using bioengineered materials, and to engineer a cell manufacturing platform that mimics the native niche for expanding these cells for cell therapy applications.”
Skeletal muscle stem cell transplantation is emerging as a promising strategy for treating muscle-associated disorders and orthopedic trauma, such as sarcopenia or open fractures often seen in car accidents, combat soldiers, or surgical resections. However, their scarcity limits their therapeutic potential. The inability to maintain and expand these cells ex vivo further compounds this challenge. Therefore, there is a critical need for a strategy to maintain and expand therapeutically potent muscle stem cells ex vivo long-term.
To date, muscle stem cell culture systems do not exist that recapitulate the asymmetric niche, consisting of myofiber and basal lamina, required to establish cellular polarity, support physiologic cell division, and guide fate specification. The contribution of active mechanical forces in modulating muscle stem cell polarity, division, and fate specification also remains overlooked.
“We are deeply honored to receive the generous support of the NIH and I am very excited to work with Dr. Han on this project,” said Robert Krauss, PhD, Mount Sinai Professor in Cell Biology and co-investigator on the study. “Dr. Han’s bioengineering approaches to muscle stem cell biology will provide important new information about how tissues regenerate, and he is highly deserving of the prestigious NIH Stephen Katz Early Stage Investigator Award.”
“Receiving this level of support from the NIH is a remarkable accomplishment,” said Leesa Galatz, MD, Mount Sinai Professor and Chair of Orthopedic Surgery at Icahn Mount Sinai and the Mount Sinai Health System. “Dr. Han’s pioneering study will provide fundamental knowledge on stem cell fate specification, and his deep expertise in biomaterials and muscle stem cell biology is bound to set him up for success.”
“The Department is thrilled that Dr. Han is among the first NIH Katz award recipients, which distinguishes him nationally as a rising star in musculoskeletal research,” said James Iatridis, PhD, Professor and Vice Chair for Research in the Department of Orthopedics. “Dr. Han’s research involves collaborations with cell biologists and shoulder surgeons, and his fundamental discoveries can be applied to engineer novel therapies to improve outcomes of orthopedic surgery patients such as those with rotator cuff injuries.”
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.